News Pfizer, Inc.

Equities

PFE

US7170811035

Real-time Estimate Cboe BZX Other stock markets 09:49:41 2024-04-25 am EDT			5-day change	1st Jan Change
26.04 ^USD	-0.89%		+3.74%	-8.51%

03:18pm	GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology	RE
12:59pm	Bristol Myers posts quarterly loss, revenue rises 5%	RE

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology	09:18am	RE
Bristol Myers posts quarterly loss, revenue rises 5%	06:59am	RE
Scholz promises support for pharma sector in Germany as Merck invests	06:11am	RE
Pfizer Keeps Q2 Dividend at $0.42 a Share, Payable June 14 to Holders of Record May 10	Apr. 24	MT
Pfizer Declares Second-Quarter 2024 Dividend	Apr. 24	BU
Pfizer Inc. Declares Second-Quarter 2024 Dividend, Payable on June 14, 2024	Apr. 24	CI
Pfizer : Political Action Committee (PAC) Report	Apr. 24	PU
Second Circuit Rules That Associational Standing For A Preliminary Injunction Requires Identifying At Least One Injured Member By Name	Apr. 24	AQ
Big pharma giants in English High Court for global Covid dispute	Apr. 24	AQ
Edwards Lifesciences Corporation: The story continues	Apr. 23
European Commission Approves Pfizer's EMBLAVEO for Patients with Multidrug-Resistant Infections and Limited Treatment Options	Apr. 23	AQ
Pfizer vs Moderna battle over COVID vaccine patents begins in UK	Apr. 23	RE
European Commission approves novel antibiotic	Apr. 22	AQ
Pfizer: new Emblaveo antibiotic approved in the EU	Apr. 22	CF
Pfizer's Emblaveo Receives European Commission Marketing Approval	Apr. 22	MT
European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options	Apr. 22	BU
European Commission Approves Pfizer?s Emblaveo® for Patients with Multidrug-Resistant Infections and Limited Treatment Options	Apr. 22	CI
Sector Update: Health Care Stocks Retreating Late Afternoon	Apr. 17	MT
Sector Update: Health Care	Apr. 17	MT
Connect Biopharma Terminates Agreement on Antiallergic Candidate With Pfizer	Apr. 17	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Pfizer, Inc: A cycle for nothing?

December 14, 2023 at 10:58 am EST

Albert Bourla, Pfizer CEO (full interview): mRNA, acquisitions, weight-loss drugs

October 31, 2023 at 04:50 pm EDT